‘Wrong Move’: Gottlieb Blasts Azar’s Perceived Regulatory Power Play Over FDA; HHS On Defense
Executive Summary
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
You may also be interested in...
US FDA Nukes HHS Decision To Exempt Medical Gloves, Other Products From Regulatory Oversight
The agency has rescinded two previous notices issued by HHS, stating the FDA had no input on the notices before they were published and the rationale backing them was flawed.
Biden’s Pick Of Becerra To Lead HHS Puts Focus On Affordable Care Act
California attorney general Xavier Becerra, who has lead the blue-state legal defense of Obamacare, is among the nominees for Biden's health care team announced on 7 December, including Rochelle Walensky for CDC director. Missing from the list, though, is a nominee for FDA commissioner or CMS administrator.
Medtech Industry Reacts To Biden’s Nomination Of ACA Defender Becerra To Lead HHS
The president-elect on 7 December named nominees for his health team, including California attorney general Xavier Becerra for HHS secretary. Missing from the list is a nominee for FDA commissioner.